2Seventy Bio Inc.

26/07/2024 | Press release | Distributed by Public on 26/07/2024 11:17

Results of Operations and Financial Condition Form 8 K

Item 2.02 Results of Operations and Financial Condition.
On July 26, 2024, 2seventy bio, Inc. (the "Company") announced that Abecma (idecabtagene vicleucel, or ide-cel) generated approximately $54 million in U.S. revenue during the second quarter of 2024. The Company and Bristol Myers Squibb ("BMS") share equally in all profits and losses related to development, manufacture and commercialization of Abecma in the U.S. This announcement is based on information provided to the Company by BMS and is unaudited and does not present all information necessary for an understanding of the Company's financial condition as of June 30, 2024 and its results of operations for the quarter then ended. The Company expects to announce its full results for the quarter ended June 30, 2024 on or before August 14, 2024.
Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the Company's anticipated revenue for the quarter ended June 30, 2024. The use of words such as "anticipate," "believe," "continue," "could," "endeavor," "estimate," "expect," "anticipate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "will" or "would" or the negative of such words or other similar expressions can be used to identify forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. These and other risks and uncertainties are described in additional detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K filed March 7, 2024 and its other filings made with the Securities Exchange Commission from time to time. Although the Company's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this Current Report on Form 8-K speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.